ArticleNanoscale2022
Size-tuneable and immunocompatible polymer nanocarriers for drug delivery in pancreatic cancer.
Article in Nanoscale, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Magnetic field-guided enhancement of nanoparticle uptake and hyperthermia efficacy in 3D tumour models.Nanoscale advances · 2026Article
- Hollow-core polydopamine nanocarriers for ultrasound-enhanced drug delivery.Nanoscale horizons · 2026Article
- Rational Design of Metal-Organic Frameworks for Pancreatic Cancer Therapy: from Machine Learning Screening to In Vivo Efficacy.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Nanoparticle-Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology.Angewandte Chemie (International ed. in English) · 2025Review
- Study on the Self-Assembly and Dual-Stimuli-Responsive Behavior of Multi-amphiphilic Polymeric Architectures.Polymer science & technology (Washington, D.C.) · 2025Article
- Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer.Polymers · 2025Review
- A 3D spheroid model for assessing nanocarrier-based drug delivery to solid tumors.npj biomedical innovations · 2025Article
- Photoacoustic polydopamine-indocyanine green (PDA-ICG) nanoprobe for detection of senescent cells.Scientific reports · 2024Article
- Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment.Acta pharmaceutica Sinica. B · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Nanocarriers have emerged as one of the most promising approaches for drug delivery. Although several nanomaterials have been approved for clinical use, the translation from lab to clinic remains challenging. However, by implementing rational design strategies and using relevant models for their validation, these challenges are being addressed. This work describes the design of novel immunocompatible polymer nanocarriers made of melanin-mimetic polydopamine and Pluronic F127 units. The nanocarrier preparation was conducted under mild conditions, using a highly reproducible method that was tuned to provide a range of particle sizes (<100 nm) without changing the composition of the carrier. A set of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.